A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Prostatic Neoplasms · Neoplasm Metastasis · Urogenital Neoplasms · Physiological Effects of Drugs · Antineoplastic Agents · Antineoplastic Agents, Hormonal · Androgens · Hormones · Hormones, Hormone Substitutes, and Hormone Antagonists · Abiraterone Acetate · Steroid Synthesis Inhibitors · Cytochrome P-450 · Enzyme Inhibitors · Prednisone · Prednisolone · Cyclin-Dependent Kinase 4 · Cyclin-Dependent Kinase 6
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 925 (final count)
- Started
- Apr 14, 2022
- Main results expected
- Feb 15, 2024
- Fully finished
- Oct 2027
- Results posted
- Jun 27, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Radiographic Progression-Free Survival (rPFS) Assessed by Investigator
Measured over: From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (up to 22 months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05288166 · record last updated 2026-07-01 · checked 2026-11-09 15:36 UTC